- Home
- OTLK vs NXN Comparison
OTLK vs NXN Comparison
Compare OTLK & NXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- NXN
- Stock Information
- Founded
- OTLK 2010
- NXN 1992
- Country
- OTLK United States
- NXN United States
- Employees
- OTLK N/A
- NXN N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- NXN Trusts Except Educational Religious and Charitable
- Sector
- OTLK Health Care
- NXN Finance
- Exchange
- OTLK Nasdaq
- NXN Nasdaq
- Market Cap
- OTLK 48.3M
- NXN 45.3M
- IPO Year
- OTLK 2016
- NXN N/A
- Fundamental
- Price
- OTLK $1.53
- NXN $11.68
- Analyst Decision
- OTLK Strong Buy
- NXN
- Analyst Count
- OTLK 5
- NXN 0
- Target Price
- OTLK $10.20
- NXN N/A
- AVG Volume (30 Days)
- OTLK 274.9K
- NXN 9.7K
- Earning Date
- OTLK 05-19-2025
- NXN 01-01-0001
- Dividend Yield
- OTLK N/A
- NXN 4.23%
- EPS Growth
- OTLK N/A
- NXN N/A
- EPS
- OTLK N/A
- NXN 0.24
- Revenue
- OTLK N/A
- NXN N/A
- Revenue This Year
- OTLK N/A
- NXN N/A
- Revenue Next Year
- OTLK $288.46
- NXN N/A
- P/E Ratio
- OTLK N/A
- NXN $48.42
- Revenue Growth
- OTLK N/A
- NXN N/A
- 52 Week Low
- OTLK $0.87
- NXN $10.64
- 52 Week High
- OTLK $9.25
- NXN $12.45
- Technical
- Relative Strength Index (RSI)
- OTLK 55.94
- NXN 61.24
- Support Level
- OTLK $1.35
- NXN $11.43
- Resistance Level
- OTLK $1.62
- NXN $11.66
- Average True Range (ATR)
- OTLK 0.10
- NXN 0.11
- MACD
- OTLK -0.00
- NXN 0.03
- Stochastic Oscillator
- OTLK 54.55
- NXN 100.00
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About NXN Nuveen New York Select Tax-Free Income Portfolio
Nuveen NY Select Tax-Free Income Port is a diversified closed-end management investment company. Its investment objective are to provide current income exempt from regular federal and New Jersey income tax, and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.